2-chloro-4-pyrazol-1-ylbenzoyl chloride | 911312-88-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-chloro-4-pyrazol-1-ylbenzoyl chloride
• 英文别名: 2-Chloro-4-pyrazol-1-ylbenzoyl chloride
• CAS: 911312-88-4
• 化学式: C₁₀H₆Cl₂N₂O
• 分子量: 241.076
• InChiKey: DDWMJWDDJLOHCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3,4,5-四氢-1H-苯并[b]氮杂卓 、 2-chloro-4-pyrazol-1-ylbenzoyl chloride 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 (2-Chloro-4-pyrazol-1-yl-phenyl)-(2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-methanone
  参考文献：
  名称：

  Novel Design of Nonpeptide AVP V₂ Receptor Agonists:  Structural Requirements for an Agonist Having 1-(4-Aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a Template

  摘要：

  The discovery of a series of nonpeptide arginine vasopressin V-2 receptor agonists is described. After identifying the aniline derivative 8 as our lead compound from the metabolites of compound 7 that showed antidiuretic activity by po administration to Brattleboro rats, improvements in the in vitro potency involving evaluations of the structural requirements for agonist action and optimizing the structure of the benzoyl moiety have been intensively undertaken. These studies led to compounds leg, 19a, and 23b,h,i that show patent; agonist activity for the V-2 receptor.

  DOI：

  10.1021/jm000108p
• 作为产物：
  描述：

  2-氯-4-氟苯甲酸甲酯 在 N-甲基吡咯烷酮 、 盐酸 、 氯化亚砜 、 potassium carbonate 、 溶剂黄146 作用下， 以 N-甲基吡咯烷酮 、 二氯甲烷 为溶剂， 反应 9.0h， 生成 2-chloro-4-pyrazol-1-ylbenzoyl chloride
  参考文献：
  名称：

  Novel Design of Nonpeptide AVP V₂ Receptor Agonists:  Structural Requirements for an Agonist Having 1-(4-Aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a Template

  摘要：

  The discovery of a series of nonpeptide arginine vasopressin V-2 receptor agonists is described. After identifying the aniline derivative 8 as our lead compound from the metabolites of compound 7 that showed antidiuretic activity by po administration to Brattleboro rats, improvements in the in vitro potency involving evaluations of the structural requirements for agonist action and optimizing the structure of the benzoyl moiety have been intensively undertaken. These studies led to compounds leg, 19a, and 23b,h,i that show patent; agonist activity for the V-2 receptor.

  DOI：

  10.1021/jm000108p

文献信息

• UREA DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE OF THESE
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1867639A1

  公开（公告）日：2007-12-19

  Urea derivatives represented by the following general formula (I) : which have an agonism of V2 receptor, are useful as agents for the treatment or prevention of diabetes insipidus, nocturia, nocturnal enuresis, overactive bladder or the like. In the formula, R1 represents a hydrogen atom or a C1-6 alkyl group which may have a substituent, R2 is a hydrogen atom or a C1-6 alkyl group, R3 is a hydrogen atom, a C1-6 alkyl group or the like, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, R7 is a hydrogen atom, a heteroaryl group which may have a substituent, a C3-8 cycloalkyl group, an amino group which may have a substituent or a C1-6 alkoxy group which may have a substituted group, M1 is a single bond, a C1-4 alkylene group or the like, Y is N or CRF (in the formula, and RF represents a hydrogen atom, a C1-6 alkyl group or the like, or pharmaceutically acceptable salts thereof, or prodrugs thereof, or pharmaceutical compositions comprising the same and pharmaceutical uses thereof.

  以下一般公式（I）所代表的尿素衍生物，具有V2受体的激动作用，可用作治疗或预防尿崩症、夜尿、夜间遗尿、膀胱过度活动等药物。在公式中，R1代表氢原子或可能具有取代基团的C1-6烷基；R2是氢原子或C1-6烷基；R3是氢原子、C1-6烷基或其他基团；R4、R5和R6独立地是氢原子、卤素原子或其他基团；R7是氢原子、可能具有取代基团的杂环烷基、C3-8环烷基、可能具有取代基团的氨基或可能具有取代基团的C1-6烷氧基；M1是单键、C1-4烷基或其他基团；Y是N或CRF（在公式中，RF代表氢原子、C1-6烷基或其他基团），或其药学上可接受的盐、前药、包含相同成分的药物组合物及其药用。
• Urea derivative, medicinal composition containing the same, and medicinal use of these
  申请人：Suzuki Ritsu

  公开号：US20080161294A1

  公开（公告）日：2008-07-03

  Urea derivatives represented by the following general formula (I): which have an agonism of V2 receptor, are useful as agents for the treatment or prevention of diabetes insipidus, nocturia, nocturnal enuresis, overactive bladder or the like. In the formula, R 1 represents a hydrogen atom or a C 1-6 alkyl group which may have a substituent, R 2 is a hydrogen atom or a C 1-6 alkyl group, R 3 is a hydrogen atom, a C 1-6 alkyl group or the like, R 4 , R 5 and R 6 are independently a hydrogen atom, a halogen atom or the like, R 7 is a hydrogen atom, a heteroaryl group which may have a substituent, a C 3-8 cycloalkyl group, an amino group which may have a substituent or a C 1-6 alkoxy group which may have a substituted group, M 1 is a single bond, a C 1-4 alkylene group or the like, Y is N or CR F (in the formula, and R F represents a hydrogen atom, a C 1-6 alkyl group or the like, or pharmaceutically acceptable salts thereof, or prodrugs thereof, or pharmaceutical compositions comprising the same and pharmaceutical uses thereof.

  以下通式（I）所表示的尿素衍生物具有V2受体激动剂作用，可用于治疗或预防尿崩症、夜尿症、夜间遗尿、过度活动膀胱等疾病。在该通式中，R1表示氢原子或C1-6烷基，可以有取代基；R2表示氢原子或C1-6烷基；R3表示氢原子、C1-6烷基或类似物；R4、R5和R6独立地表示氢原子、卤素原子或类似物；R7表示氢原子、可以有取代基的杂环芳基、C3-8环烷基、可以有取代基的氨基或可以有取代基的C1-6烷氧基；M1表示单键、C1-4烷基等；Y表示N或CRF（在该式中，RF表示氢原子、C1-6烷基或类似物）；以及其药学上可接受的盐、前药或包含它们的制剂，以及其医药用途。
• [EN] BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS<br/>[FR] MOLÉCULES DE PETITE TAILLE CONTENANT DU BORE EN QUALITÉ D'AGENTS ANTI-PROTOZOAIRES
  申请人：ANACOR PHARMACEUTICALS INC

  公开号：WO2014121124A1

  公开（公告）日：2014-08-07

  This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.

  这项发明提供了一些新化合物，可用于治疗原虫感染，包括含有这些化合物的制药组合物，以及这些化合物与至少一种其他治疗有效剂的组合。
• Novel Design of Nonpeptide AVP V₂ Receptor Agonists:  Structural Requirements for an Agonist Having 1-(4-Aminobenzoyl)-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepine as a Template
  作者：Kazumi Kondo、Hidenori Ogawa、Tomoichi Shinohara、Muneaki Kurimura、Yoshihisa Tanada、Keizo Kan、Hiroshi Yamashita、Shigeki Nakamura、Takahiro Hirano、Yoshitaka Yamamura、Toyoki Mori、Michiaki Tominaga、Akiko Itai

  DOI：10.1021/jm000108p

  日期：2000.11.1

  The discovery of a series of nonpeptide arginine vasopressin V-2 receptor agonists is described. After identifying the aniline derivative 8 as our lead compound from the metabolites of compound 7 that showed antidiuretic activity by po administration to Brattleboro rats, improvements in the in vitro potency involving evaluations of the structural requirements for agonist action and optimizing the structure of the benzoyl moiety have been intensively undertaken. These studies led to compounds leg, 19a, and 23b,h,i that show patent; agonist activity for the V-2 receptor.